Vanguard Global Advisers »

Acrivon Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Acrivon Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Acrivon Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acrivon Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $6.2k 4.5k 1.39

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Acrivon Therapeutics

RA Capital Management
Sands Capital Ventures
Wellington Management Company
Acadian Asset Management
Vanguard Capital Management
Vanguard Group
Renaissance Technologies
Marshall Wace
Acorn Capital Advisors
Two Sigma Investments
Jane Street
Geode Capital Management
BlackRock
GSA Capital Partners
Vanguard Fiduciary Trust

View all funds holding Acrivon Therapeutics